BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/27/2025 10:57:49 AM | Browse: 124 | Download: 206
 |
Received |
|
2025-06-05 13:22 |
|
Peer-Review Started |
|
2025-06-07 00:23 |
|
First Decision by Editorial Office Director |
|
2025-07-11 07:30 |
|
Return for Revision |
|
2025-07-11 13:35 |
|
Revised |
|
2025-07-23 11:37 |
|
Publication Fee Transferred |
|
2025-07-26 11:40 |
|
Second Decision by Editor |
|
2025-09-01 02:47 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-09-01 07:17 |
|
Articles in Press |
|
2025-09-01 07:17 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-10-17 06:16 |
|
Publish the Manuscript Online |
|
2025-10-27 10:57 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Basic Study |
| Article Title |
Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shu Niu, Shu-Chun Chen, Chen-Xi Wang, Lin Yue and Shu-Qi Wang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The Scientific Research Programme on Traditional Chinese Medicine in Hebei Province |
No. 2024127 |
|
| Corresponding Author |
Shu-Chun Chen, PhD, Professor, Department of Endocrinology, Hebei General Hospital, No. 348 Heping West Road, Shijiazhuang 050051, Hebei Province, China. chenshuc2014@163.com |
| Key Words |
Metabolic dysfunction-associated steatotic liver disease; Semaglutide; Empagliflozin; Lysophosphatidylcholine; Metabolomics |
| Core Tip |
The present study demonstrated that semaglutide and empagliflozin reduced body weight, ameliorated disorders of glucose and lipid metabolism, lowered levels of inflammation and oxidative stress, and attenuated metabolic dysfunction-associated steatotic liver disease in obese mice. The following section outlines possible mechanisms for reducing the levels of various lysophosphatidylcholines. |
| Publish Date |
2025-10-27 10:57 |
| Citation |
Niu S, Chen SC, Wang CX, Yue L, Wang SQ. Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice. World J Hepatol 2025; 17(10): 110402 |
| URL |
https://www.wjgnet.com/1948-5182/full/v17/i10/110402.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v17.i10.110402 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
